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ABSTRACT
Objectives  To investigate the expression and 
activation of mitogen-activated protein kinases in 
patients with early arthritis who are disease-modifying 
antirheumatic drug (DMARD) naïve.
Methods  A total of 50 patients with early arthritis who 
were DMARD naïve (disease duration <1 year) were 
prospectively followed and diagnosed at baseline and 
after 2 years for undifferentiated arthritis (UA), rheumatoid 
arthritis (RA) (1987 American College of Rheumatology 
(ACR) and 2010 ACR/European League Against 
Rheumatism (EULAR) criteria), or spondyloarthritis (SpA). 
Synovial biopsies obtained at baseline were examined for 
expression and phosphorylation of p38, extracellular signal 
regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) 
by immunohistochemistry and digital analysis. Synovial 
tissue mRNA expression was measured by quantitative 
PCR (qPCR).
Results  ERK and JNK activation was enhanced at 
inclusion in patients meeting RA criteria compared 
to other diagnoses. JNK activation was enhanced 
in patients diagnosed as having UA at baseline who 
eventually fulﬁ  lled 1987 ACR RA criteria compared 
to those who remained UA, and in patients with RA 
fulﬁ  lling 2010 ACR/EULAR criteria at baseline. ERK 
and JNK activation was enhanced in patients with RA 
developing progressive joint destruction. JNK activation 
in UA predicted 1987 ACR RA classiﬁ  cation criteria 
fulﬁ  lment (R2=0.59, p=0.02) after follow-up, and 
disease progression in early arthritis (R2=0.16, p<0.05). 
Enhanced JNK activation in patients with persistent 
disease was associated with altered synovial expression 
of extracellular matrix components and CD44.
Conclusions  JNK activation is elevated in RA before 
1987 ACR RA classiﬁ  cation criteria are met and predicts 
development of erosive disease in early arthritis, 
suggesting JNK may represent an attractive target in 
treating RA early in the disease process.
INTRODUCTION
Mitogen-activated protein kinase (MAPK) family 
members, namely p38 kinases (α–δ), extracellular 
signal regulated kinases (ERKs) 1 and 2, and c-Jun 
N-terminal kinase (JNKs) 1–3, occupy critical posi-
tions in coupling diverse cell surface proteins, 
including antigen receptors, tumour necrosis factor 
(TNF) family receptors, chemokine and cytokine 
receptors, and Toll-like receptors to inﬂ  ammatory 
gene expression.1 2 Members of each MAPK fam-
ily are expressed and activated in synovial tissue of 
patients with rheumatoid arthritis (RA) and other 
forms of inﬂ  ammatory  arthritis.3–5 Highly selec-
tive pharmacological inhibitors of p38,6–9 ERK10 11 
and JNK3 12 13 prevent inﬂ  ammatory activation of 
stromal ﬁ  broblast-like synoviocytes (FLS) derived 
from synovial tissue, chondrocytes and osteoclasts 
from patients with RA. Additionally, pharmacolog-
ical inhibition or genetic deletion of MAPK activity 
reduces inﬂ  ammation and joint destruction in mul-
tiple experimental animal models of RA.6 8 10 12 14–18 
These data collectively suggest that therapeutic 
strategies inhibiting MAPK activation may be use-
ful in the treatment of RA.1 2 19 20
Despite this wealth of preclinical analyses, little 
is known about the distinct contributions of each 
MAPK to the onset and perpetuation of RA. Clinical 
parameters and biomarkers have yet to be identiﬁ  ed 
which are associated with synovial MAPK activa-
tion status, and MAPK activation in RA has primar-
ily been examined in patients with destructive 
end-stage disease.3–5 In the transgenic human TNF 
model of murine arthritis, p38 activation is required 
for induction of inﬂ   ammation and joint destruc-
tion.15 21 Whether this observation can be trans-
lated into successful treatment of RA with MAPK 
inhibitors, especially in early disease, is uncertain 
however, as clinical trials with p38 inhibitors have 
not been successful.22 23 Recent kinetic analyses of 
MAPK activation in experimental murine arthri-
tis have revealed model-speciﬁ  c differences in the 
degree of p38, ERK and JNK activation, as well as in 
the timing of their activation during disease onset 
and resolution.24 Here, we examined if similar dif-
ferences in MAPK involvement might be relevant 
to the earliest stages of the development of RA, by 
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assessing the relationship between MAPK expression and activa-
tion, and disease diagnosis and outcome in a prospective cohort 
of patients with early arthritis who were disease-modifying anti-
rheumatic drug (DMARD) naïve.
PATIENTS AND METHODS
Patients
A total of 50 patients with arthritis of duration of less than 1 
year, as measured from the ﬁ  rst clinical signs of arthritis, irre-
spective of which joint was initially affected, and a clinically 
inﬂ   amed knee, ankle or wrist joint, underwent arthroscopic 
synovial biopsy. Diagnosis of RA or spondyloarthritis (SpA) 
was made according to established classiﬁ  cation  criteria.25–28 
Patients were classiﬁ  ed as having undifferentiated arthritis (UA) 
if no classifying diagnosis for RA, SpA or other forms of arthritis 
could be made. After 2 years of follow-up ﬁ  nal diagnosis was 
made according to classiﬁ  cation criteria. All patients were naïve 
to treatment with DMARDs and corticosteroids at inclusion, 
and after baseline study procedures all patients were treated 
consistent with European League Against Rheumatism (EULAR) 
guidelines.29 In case of a clinical diagnosis of RA, DMARD treat-
ment was initiated directly after baseline study procedures were 
completed. The 28-joint Disease Activity Score (DAS28) was 
systematically determined and patients were treated accord-
ing to the treat-to-target principle, aiming for DAS28 <2.6, 
using conventional DMARDs, corticosteroids and biologicals, 
if indicated. If a combination of DMARDs did not result in a 
DAS28 <3.2 then a biological was given. Upon decision of the 
treating doctor corticosteroids were given in combination with 
a DMARD, either high dose and tapered down in 6–8 weeks 
or more prolonged low dose. In case of a diagnosis of SpA 
with peripheral arthritis, all patients, except patients with reac-
tive arthritis were started on methotrexate. The patients with 
reactive arthritis were treated with intra-articular steroids and 
non-steroidal anti-inﬂ  ammatory drugs. Treatment was aimed at 
minimal disease activity. Patients with UA were treated with 
intra-articular steroids and, if arthritis was persistent, a DMARD 
was given.
At inclusion we assessed disease activity (68 tender and 66 
swollen joint score, patient’s visual analogue scale (VAS) of global 
disease activity (scale 0–100 mm), VAS of pain (scale 0–100 mm), 
erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP) levels) and collected serum and arthroscopic synovial tis-
sue biopsy samples. X-rays were obtained at baseline and after 
2 years; erosion scoring was based on the presence or absence of 
erosions on x-rays of hands and feet where the modiﬁ  ed Sharp-
van der Heijde erosion score was ≥1.30 This study was approved 
by the institutional review board, performed according to the dec-
laration of Helsinki. All study patients provided written informed 
consent.
Measurement of serum autoantibodies
Patient serum immunoglobulin M rheumatoid factor (IgM-RF) 
and anti-citrullinated protein antibodies (ACPA) were measured 
using IgM-RF (Sanquin, Amsterdam, The Netherlands) and anti-
cyclic citrullinated peptide 2 (CCP2) (Eurodiagnostica, Arnhem, 
The Netherlands) ELISA kits.
Synovial tissue biopsy sampling, immunohistochemistry and 
gene expression
All patients underwent arthroscopic synovial tissue biopsy 
sampling of an actively inﬂ  amed ankle, wrist or knee joint.31 
Synovial tissue biopsies were collected from each patient, 
stored and processed for immunohistochemistry, and stained 
sections analysed by digital imaging analysis as previously 
described.32–34 Detailed descriptions of stainings, analyses and 
mRNA expression studies are provided in the supplementary 
methods.
Statistics
Statistical analysis was performed using Windows GraphPad 
Prism 4 (GraphPad Software, La Jolla, California, USA) and SPSS 
V.16.0 (SPSS, Chicago, Illinois, USA) software. Comparisons 
in expression or phosphorylation of markers between cohorts 
were performed using the Mann–Whitney U test, ﬁ  rst using the 
Kruskal–Wallis test when more than two groups were compared. 
Logistic regression analysis was used to analyse the relationship 
between relative MAPK phosphorylation and development of 
RA and the development of erosive disease. Results were con-
sidered statistically signiﬁ  cant if p<0.05.
RESULTS
p38, ERK and JNK are differentially expressed and 
phosphorylated in patients with early arthritis with distinct 
diagnoses
We performed immunohistochemical staining on synovial 
biopsy samples using antibodies recognising total and p-p38, 
ERK and JNK MAPKs. Within the cohort, 27 patients were 
diagnosed as having RA at 2 years after enrolment in the study 
based on 1987 American College of Rheumatology (ACR) crite-
ria for RA, 7 with SpA and 16 with UA. Clinical characteristics 
of each patient group are shown in table 1. p38 expression was 
highest in UA, and signiﬁ  cantly different in this group com-
pared to SpA (p<0.05), but not RA (supplementary ﬁ  gure 1). 
The p-p38 levels were higher in UA than SpA (p<0.05). ERK 
expression was signiﬁ  cantly higher in RA than SpA (p<0.01) 
and UA (p<0.01) (supplementary ﬁ  gure 1). p-ERK levels were 
also highest in RA, where it was elevated compared to SpA 
(p<0.01) and UA (p<0.01). No differences in JNK expression 
were noted between diagnostic groups (supplementary ﬁ  gure 
1), but p-JNK levels were higher in RA than in SpA (p<0.005) 
and UA (p<0.01). Within each diagnostic group, and across 
the cohort as a whole, no signiﬁ  cant correlation was observed 
between MAPK expression and phosphorylation levels, sug-
gesting that phosphorylation was driven by differential inﬂ  am-
matory stimuli input (data not shown, see supplementary ﬁ  gure 
2 for representative photomicrographs of staining distribution 
in each diagnostic group).
Relative phosphorylation of ERK and JNK is enhanced in 
patients with early RA
To gain insight into the degree of MAPK engagement by inﬂ  am-
matory stimuli, we calculated the relative phosphorylation of 
p38, ERK and JNK proteins for each patient (IOD phospho-
MAPK/IOD total MAPK, arbitrary units). Relative p38 phos-
phorylation was similar in all diagnostic groups (ﬁ  gure  1A, 
left panel). In contrast, relative ERK phosphorylation in RA 
was higher than in SpA (p<0.05) and UA (p<0.01) (ﬁ  gure 1A, 
middle panel). Relative JNK phosphorylation (ﬁ  gure 1A, right 
panel) was elevated in RA compared to UA (p<0.01) and SpA 
(p<0.005). Using 2010 ACR/EULAR classiﬁ   cation criteria, 35 
patients were diagnosed as having RA, 7 with SpA and 8 with 
UA at baseline (supplementary table 1). Here, no differences in 
relative p38 or ERK phosphorylation were observed, but relative 
JNK phosphorylation was elevated in RA (p<0.001) compared 
to SpA (ﬁ  gure 1B).
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Figure 1  Relative mitogen-activated protein kinase (MAPK) activation in relation to disease diagnosis. Quantitative comparison of relative MAPK 
phosphorylation in the synovial tissue of patients with early arthritis. Tissue sections from patients diagnosed as having rheumatoid arthritis (RA) 
according to 1987 American College of Rheumatology (ACR) criteria, spondyloarthritis (SpA) and undifferentiated arthritis (UA) after 2 years of 
follow-up were stained with antibodies against phospho- and total p38, extracellular-signal regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). 
Stainings were developed with biotin tyramide enhancement, horseradish peroxidase and aminoethylcarbazole, followed by counterstaining with 
Mayer’s haematoxylin, and evaluated by digital imaging analysis. Relative phosphorylation levels (ratio of IOD phosphorylated protein to IOD of total 
protein, arbitrary units) of p38, ERK and JNK were calculated for patients diagnosed as having RA according to (A) 1987 ACR criteria and (B) 2010 
ACR/European League Against Rheumatism (EULAR) criteria, SpA and UA. Data are presented as boxplots, where the boxes represent the 25th to 
75th percentiles, the lines within the box mark the median value, and lines outside the boxes denote the 10th and 90th percentiles. Lines connecting 
data sets indicate statistically signiﬁ  cant differences between groups. *p<0.05; **p<0.01; ***p<0.005.
Table 1  Characteristics of study patients
UA>>UA, n=16 RA, n=19 UA>>RA, n=8 SpA, n=7
Age, years 39 (20–67) 53 (22–82) 54 (43–66) 44 (20–56)
Female, n 12 10   7 0
Disease duration, months   4 (1–10)   5 (1–12) 4 (1–11) 2 (1–12)
VAS, 0–100 63 (9–93) 37 (11–99) 48 (32–98) 35 (17–91)
TJC68, n   3 (0–37) 16 (5–38) 13 (3–25) 4 (0–11)
SJC66, n   1 (1–19)   8 (4–41) 6 (1–20) 2 (1–5)
ESR, mm/h 34 (4–85) 32 (3–91) 30 (14–77) 11 (3–47)
CRP, mg/litre 11 (2–58) 12 (3–133) 173–42 7 (1–46)
IgM-RF positive, n 2 13 1 0
ACPA positive, n 2 10 3 0
No DMARDs 12 0 0 2
DMARD monotherapy 3 15 4 5
≥2 DMARDs 1 4 2 0
≥2 MTX plus anti-TNF 0 0 2 0
Patients were classiﬁ  ed as having rheumatoid arthritis (RA) based on 1987 American College of Rheumatology (ACR) 
criteria. UA>>UA=undifferentiated arthritis (UA) at baseline and at 2 years of follow-up; UA>>RA=classiﬁ  ed as 
having UA at baseline and diagnosed as having RA at 2 year follow-up.
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; 
ESR, erythrocyte sedimentation rate; IgM-RF, immunoglobulin M rheumatoid factor; MTX, methotrexate; SpA, 
spondyloarthritis; SJC66, 66-joint swollen joint count; TJC68, 68-joint tender joint count; TNF, tumour necrosis factor α; 
VAS, visual analogue scale of global disease activity.
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Figure 2  Relative mitogen-activated protein kinase (MAPK) activation in relation to disease outcome and progression. A. Quantitative comparison 
of relative MAPK phosphorylation in the synovial tissue of patients classiﬁ  ed according to 1987 American College of Rheumatology (ACR) criteria as 
undifferentiated arthritis (UA) which remained UA after 2 years (UA>>UA), and UA which was diagnosed as rheumatoid arthritis (RA) after 2 years 
(UA>>RA). Relative phosphorylation levels of p38, extracellular signal regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) were calculated 
for patients diagnosed as having UA>>UA and UA>>RA. B. Quantitative comparison of relative MAPK phosphorylation in the synovial tissue of 
patients classiﬁ  ed as having RA after 2 years based on 1987 ACR criteria (upper panels) and all patients with early arthritis with persistent erosive 
and persistent non-erosive disease (lower panels). 
Relative phosphorylation of ERK and JNK is enhanced in patients 
with early RA before fulﬁ  lment of 1987 ACR RA classiﬁ  cation 
criteria
We next compared MAPK activation with the presence of RF 
and ACPA, autoantibodies predictive of the development, dis-
ease course and prognosis of RA.35 36 Patients with RA and 
UA receiving a diagnosis of RA at 2 year follow-up (UA>>RA) 
identiﬁ  ed by 1987 ACR criteria were grouped based on the 
absence or presence of serum RF or ACPA at baseline (see 
supplementary tables 2 and 3 for patient clinical characteris-
tics). Relative activation of ERK (p<0.0005) and JNK (p<0.005) 
was signiﬁ  cantly higher in patients who were RF+ (n=14) than 
RF– (n=13). Patients who were ACPA+ (n=13) also displayed 
enhanced ERK (p<0.001) and JNK (p<0.005) activation com-
pared to patients who were ACPA– (n=14) (supplementary 
ﬁ  gure 3).
Given that ERK and JNK activation was elevated in patients 
who were RF and ACPA seropositive, we next examined if 
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ERK and JNK might already be activated in UA>>RA, as diag-
nosed by 1987 ACR criteria (see table 1 for patient character-
istics). We observed no differences in relative p38 (ﬁ  gure 2A, 
left panel) or ERK (ﬁ  gure 2A, middle panel) phosphorylation 
between patients diagnosed as having UA who remained 
UA (UA>>UA) (n=16) and patients who progressed from 
UA>>RA (n=8). In contrast, JNK phosphorylation was elevated 
in UA>>RA (ﬁ   gure 2A, right panel) compared to UA>>UA 
(p<0.005). Univariate logistic regression analysis showed that 
relative JNK activation at baseline was signiﬁ  cantly  related 
to fulﬁ  lment of classiﬁ  cation criteria for RA after follow-up 
with an explained variance of 59% (R2=0.59, p=0.02). Thus, 
in patients with early arthritis, elevated ERK and JNK activ-
ity distinguish RA from other forms of arthritis, and JNK acti-
vation is elevated in patients with RA even before 1987 ACR 
classiﬁ  cation criteria of RA are met. Similar regression analyses 
based on 2010 ACR/EULAR classiﬁ  cation criteria could not 
be performed due to the small number (n=2) of patients with 
UA>>UA (supplementary ﬁ  gure 4).
Relative ERK and JNK activation is elevated in patients with RA 
developing erosive disease
To examine the relationship between MAPK activation and 
disease outcome in patients with RA, RA>>RA and UA>>RA 
were pooled and grouped based on the development of erosive 
disease (deﬁ   ned as a modiﬁ   ed Sharp-van der Heijde erosion 
score was ≥1 at 2 year follow-up, see table 2 for patient clini-
cal characteristics).30 Only one patient with early arthritis had 
erosive disease at baseline. Relative p38 phosphorylation was 
similar between patients with RA with non-erosive (n=15) and 
erosive disease (n=12) (ﬁ  gure 2B, upper left panel). Relative ERK 
(p<0.01) (ﬁ  gure 2B, upper middle panel) and JNK phosphoryla-
tion (p<0.01) (ﬁ  gure 2B, upper right panel) was higher in patients 
developing erosive disease. Examining all patients with early 
arthritis, regardless of diagnosis (see table 3 for patient char-
acteristics), activation of p38 (p<0.05), ERK (p<0.005) and JNK 
(p<0.001) was elevated in patients with erosive disease (ﬁ  gure 
2B, lower panels). JNK activation, but not p38 or ERK activation, 
predicted development of erosive disease (R2=0.16, p<0.05).
Table 2  Characteristics of patients with rheumatoid arthritis (RA) with erosive and non-erosive 
disease
RA erosive, n=12 RA non-erosive, n=15 p Value
Age, years 53 (24–82) 54 (22–58) 0.88
Disease duration, months   5 (1–10)   4 (1–12) 0.86
DAS28  5.0  (2.9–6.6)  5.9  (3.3–6.7) 0.13
ESR, mm/h 37 (3–91) 27 (7–76) 0.67
CRP, mg/litre   9 (3–114) 16 (3–133) 0.62
VAS, 0–100 27 (11–76) 50 (25–98) 0.12
IgM-RF positive, % 66 43 0.27
ACPA positive, % 44 50 0.80
DMARD monotherapy 9 8
≥2 DMARDS 3 5
MTX plus anti-TNFα 02
Patients were classiﬁ  ed as having rheumatoid arthritis (RA) based on 1987 American College of Rheumatology (ACR) 
criteria.
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, 
disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; IgM-RF, immunoglobulin M rheumatoid 
factor; MTX, methotrexate; TNF, tumour necrosis factor; VAS, visual analogue scale of global disease activity.
Figure 2 (Continued)  C. Comparison of relative MAPK phosphorylation in the synovial tissue of patients classiﬁ  ed with RA according to 2010 
ACR/EULAR criteria displaying self-limiting, persistent non-erosive and erosive disease. Erosive disease was deﬁ  ned by a Sharp-van der Heijde 
erosion score ≥1 at 2 year follow-up. Relative MAPK phosphorylation was calculated as the ratio of IOD phosphorylated protein to IOD of total protein 
(arbitrary units). Data are presented as boxplots, where the boxes represent the 25th to 75th percentiles, the lines within the box mark the median 
value, and lines outside the boxes denote the 10th and 90th percentiles. Lines connecting data sets indicate statistically signiﬁ  cant differences 
between groups. *p<0.05; **p<0.01; ***p<0.005.
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Relative JNK activation and is enhanced in patients with 
persistent disease
Among patients who fulﬁ  lled 2010 ACR/EULAR criteria for RA 
after 2 years of follow-up, 17 patients had persistent non-erosive 
disease, 12 had erosive disease and 10 had self-limiting disease 
(supplementary table 4). ERK activation (ﬁ  gure 2C) was elevated 
in patients with erosive disease compared to those with self-
limiting disease (p<0.005), and a trend towards enhanced ERK 
activation was observed in patients with erosive disease com-
pared to those with persistent non-erosive disease (p=0.051). 
Figure 3  Gene expression analysis in synovial tissue of patients with early rheumatoid arthritis (RA) with self-limiting and persistent disease. A. 
Supervised hierarchical cluster analysis of expression of 83 genes involved in extracellular matrix (ECM) biology and cellular adhesion. Analysis was 
performed on patients with RA, undifferentiated arthritis (UA)>>UA and UA>>RA, pooled and grouped based on self-limiting (n=8) and persistent 
(n=14) disease. Each column represents the data of one patient and each row shows the relative expression of a given gene for all patients. Gene 
designations are listed at the right of the ﬁ  gure. Red signiﬁ  es relatively higher expression of a given gene, green relatively lower expression and black 
signiﬁ  es equivalence to the median expression of that gene across all patients. B. Relative mRNA expression of selected genes in patients with self-
limiting and persistent disease, expressed as the ratio between the gene of interest and ribosomal protein L13a (RPL13A). Each data point represents 
a value for an individual patient and bars represent mean values. *p<0.05.
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Table 3  Characteristics of patients with early arthritis with erosive and non-erosive disease
Erosive, n=17 Non-erosive, n=33 p Value
Age, years 54 (24–81) 46 (20–75) 0.92
Disease duration, months   6 (1–11)   5 (1–12) 0.39
DAS28  3.7  (1.1–5.7)  2.4  (0.6–6.3) 0.012
ESR, mm/h 36 (3–91) 32 (9–93) 0.72
CRP, mg/litre 14 (1–114) 10 (1–133) 0.68
VAS, 0–100 42 (11–81) 38 (3–98) 0.88
IgM-RF positive, % 35 21 0.32
ACPA positive, % 24 27 0.88
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; 
ESR, erythrocyte sedimentation rate; IgM-RF, immunoglobulin M rheumatoid factor; VAS, visual analogue 
scale of global disease activity.
JNK activation was signiﬁ  cantly lower in those patients with 
RA with self-limiting disease compared to those with persistent 
(p<0.005) and erosive disease (p<0.01), associated with lower 
scores for tender joint count, swollen joint count and DAS28 
(supplementary table 4).
As JNK activation was elevated in persistent disease, and 
often associated with the regulation of expression extracellu-
lar matrix (ECM) component biology and cellular interactions 
with the ECM, we examined expression of a targeted gene set 
in patients with RA from this cohort with self-limiting (n=8) 
and persistent (non-erosive and erosive, n=14) disease from 
which mRNA was available. Quantitative PCR (qPCR) analy-
sis was performed on approximately 80 genes encoding ECM 
components, matrix metalloproteinases (MMPs) and adhesion 
molecules. Unsupervised hierarchical cluster analysis of gene 
products failed to group patients according to disease outcome 
(data not shown), and no trends toward similar gene expression 
patterns were observed using supervised hierarchical clustering 
(ﬁ  gure 3A). However, analysis of expression of each individual 
gene (ﬁ  gure 3B and supplementary table 5) revealed that expres-
sion of collagens COL1A1,  COL4A2,  COL5A1,  COL6A1 and 
COL16A1, the laminin LAMC1 and MMP-12 were signiﬁ  cantly 
downregulated in patients with persistent disease, while expres-
sion of CD44 was elevated (all p<0.05).
DISCUSSION
Because p38, ERK and JNK are each detected in their activated 
form in the synovial tissue of patients with various forms of 
inﬂ  ammatory arthritis, and are requisite for pathology in animal 
models of arthritis, MAPKs might represent attractive therapeu-
tic targets in the treatment of RA and other forms of arthritis.1–4 
However, the clinical inefﬁ  cacy of p38 inhibitors in early trials 
with patients with RA has indicated a need for a greater under-
standing of the contributions of MAPKs to synovitis and joint 
destruction.22 23 37 Intriguingly, recent kinetic analyses of MAPK 
activation in multiple murine models of RA have also indicated 
model-speciﬁ  c differential involvement of each MAPK in dis-
tinct phases of initiation, perpetuation and resolution of dis-
ease.24 This latter observation prompted us to examine MAPK 
expression and phosphorylation in the earliest stages of human 
arthritis.
We ﬁ  nd that synovial activation of ERK and JNK, but not p38, 
is signiﬁ  cantly elevated in patients with RA compared to patients 
with other diagnoses, as well as in patients who develop erosive 
RA. Perhaps important to the aetiology of RA, JNK activation is 
elevated in patients with RA even before 1987 ACR classiﬁ  cation 
criteria of RA are met. Assessing all patients with early arthritis, 
regardless of disease diagnosis, we found that each MAPK was 
more highly activated in patients with erosive disease, but here, 
only JNK activation predicted the development of erosive dis-
ease. Forward and backward linear regression failed to identify 
roles for p38 and ERK in diagnosis and disease progression (data 
not shown). Further studies in larger independent cohorts will 
obviously be needed to assess the positive predictive value and 
the negative predictive value of JNK activation in predicting RA 
and erosive disease.
We found no evidence supporting a role for p38 in the onset of 
RA or eventual joint destruction in arthritis. Phosphorylated p38 
is readily detected in the synovial tissue of patients with active 
and end-stage destructive RA, and mice in the human TNF-
transgenic model of RA.3 4 21 In these mice, pharmacological 
p38 inhibition blocks disease onset.15 However, p38 activation 
in murine collagen-induced arthritis is only modestly increased 
over baseline until late in disease (day 40–50), when clinical 
parameters and cytokine biomarkers of disease activity recede.24 
Also, p38 activity is not affected in TNF-transgenic mice follow-
ing anti-TNF treatment, or in patients with psoriatic arthritis 
treated with etanercept.21 38 Thus, p38 may contribute signiﬁ  -
cantly to negative feedback mechanisms dampening inﬂ  amma-
tory responses or repairing tissue in established RA.39 In patients 
with early arthritis p38-dependent repair mechanisms may not 
yet have been initiated.
ERK phosphorylation is also elevated in patients with early 
arthritis diagnosed as having RA and in patients with RA who 
develop erosive disease. ERK phosphorylation is also readily 
detected in the synovial tissue of patients with RA undergo-
ing joint replacement.4 The extent and timing of ERK activation 
in experimental arthritis is heavily model-dependent, although 
genetic or pharmacological suppression of ERK appears to 
uniformly suppress disease.10 17 24 However, as in vitro stud-
ies in RA FLS have revealed that many secreted products rou-
tinely assessed as TNF-dependent activation markers relevant 
to RA are relatively insensitive to ERK inhibition. Thus, the 
mechanisms by which ERK contributes to inﬂ  ammation and 
disease progression in the earliest stages of RA remain to be 
established.9
Strikingly, JNK phosphorylation is signiﬁ   cantly elevated in 
synovial tissue from patients with early RA, even before 1987 
ACR classiﬁ  cation criteria are met. During the course of our 
study, new classiﬁ  cation criteria for the diagnosis of RA were 
deﬁ  ned,27 28 and re-examining our cohort with these criteria, 
we found that half of the patients originally classiﬁ  ed as hav-
ing UA at baseline now met criteria for RA, similar to a recent 
study.40 Importantly, using the new criteria, we conﬁ  rmed that 
relative JNK activity is enhanced in early RA. However, insuf-
ﬁ  cient numbers of patients could be classiﬁ  ed as UA>>UA to 
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allow logistic regression analysis to determine whether JNK 
activity at baseline was predictive of fulﬁ  lment of RA accord-
ing to the 2010 ACR/EULAR criteria after follow-up. We also 
conﬁ  rmed that ERK activation is enhanced in patients with RA 
who develop erosive disease. Finally, with the new criteria we 
identiﬁ  ed a subset of patients that fulﬁ  l 2010 ACR/EULAR cri-
teria for RA at baseline, but have low levels of JNK activity and 
self-limiting disease.
Synovial JNK phosphorylation has previously been detected 
in patients with longstanding RA, and JNK contributes to inter-
leukin 1β-induced collagenase expression, inﬂ  ammation  and 
joint destruction in murine arthritis models.12 18 41 Additionally, 
JNK signalling drives collagenase-3 expression and bone dam-
age in rat adjuvant-induced arthritis.12 These studies have indi-
cated a role for JNK in regulating synovial ECM biology, or cell 
interactions with the ECM. Comparing patients with early 
arthritis with self-limiting disease versus those with persistent 
disease, either non-erosive or erosive, we ﬁ  nd that enhanced 
JNK activation is associated with decreased expression of 
developmentally important ECM components, including sev-
eral forms of collagen, laminin C1 and MMP-12. We also ﬁ  nd 
that CD44 expression is elevated in patients with early arthri-
tis who develop persistent disease. CD44 is thought to have 
an important role in the pathology of RA, acting as an adhe-
sion molecule and ECM component ligand for endothelial cells, 
macrophages, lymphocytes and FLS.42 Speciﬁ  c splice variants 
of CD44 are associated with invasive FLS behaviour in RA.43–46 
Also, a pathogenic role for CD44 has been demonstrated in ani-
mal arthritis models.42 47 Further studies will determine if there 
is a direct relationship between expression of these genes and 
JNK activity in patients with early arthritis, and if so, whether 
JNK activation regulates or responds to these genes. Our studies 
indicate that evaluation of JNK activity might be of additional 
diagnostic and prognostic value to the new classiﬁ  cation crite-
ria, and that pharmacological targeting of JNK and ERK may be 
of beneﬁ  t in limiting inﬂ  ammation and joint destruction early in 
the development of RA.
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